Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | FECH | P22830 | 1/20 | 0.41 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.41 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29888002 | 0.91 | ERBB2 (0.43) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL24569727 | 0.91 | ERBB2 (0.43) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL29888005 | 0.91 | ERBB2 (0.43) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL24569815 | 0.91 | ERBB2 (0.43) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL24569812 | 0.85 | EGFR (0.43) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL24569614 | 0.85 | ERBB2 (0.59) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL24569623 | 0.85 | EGFR (0.41) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL24569476 | 0.83 | ERBB2 (0.44) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL24569473 | 0.83 | ERBB2 (0.44) | EGFRERBB2NQO2FECHMYH14 | |
| SCHEMBL29888061 | 0.83 | ERBB2 (0.44) | EGFRERBB2NQO2FECHMYH14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022140769-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |